Skip to main content

Table 3 GPx polymorphism and parameter stratification by CHD status

From: MnSOD and GPx1 polymorphism relationship with coronary heart disease risk and severity

Trait Controls (203) Cases (164) P
Age (years) 60.63 ± 12.27 62.98 ± 11.89 0.07
Body mass index (kg/m2) 24.73 ± 3.52 28.05 ± 3.17 <10 −4
Male, n (%) 119 (58.62 %) 97 (59.15 %) 0.92
Hypertension, n (%) 13 (6.40 %) 96 (58.54 %) <10 −4
Diabetes mellitus, n (%) 10 (4.93 %) 59 (35.98 %) <10 −4
Plasma glucose (mmol/l) 4.33 ± 0.71 4.47 ± 2.91 0.51
LDL cholesterol (mmol/l) 2.54 ± 1.12 3.28 ± 1.13 <10 −4
HDL cholesterol (mmol/l) 0.83 ± 0.37 0.82 ± 0.27 0.77
Triglycerides (mmol/l) 1.24 ± 0.64 1.31 ± 0.77 0.34
Non enzymatic antioxidant parameters
 Uric Acid (µmol/l) 312.96 ± 92.00 335.82 ± 147.99 0.07
 Total bilirubin (µmol/l) 17.04 ± 4.73 7.68 ± 4.81 <10 −4
 Direct bilirubin (µmol/l) 7.34 ± 3.21 2.36 ± 1.08 <10 −4
 Albumin (g/l) 41.74 ± 6.05 40.78 ± 4.18 0.09
 Iron (µmol/l) 18.23 ± 4.94 16.38 ± 3.47 <10 −4
Enzymatic antioxidant parameters
 GPx activity, (U/gHb) 42.17 ± 13.99 40.20 ± 12.25 0.16
 TAS (mmol/l) 1.68 ± 0.26 1.37 ± 0.25 <10 −4
 GPx genotypes (%), n (CC/CT/TT) 43.84/44.34/11.82 % 55.49/37.80/6.71 % 0.051
89/90/24 91/62/11 0.1
 GPx genotypes (%), n (CC + CT/TT) 88.18/11.82 % 93.29/6.71  
179/24 153/11  
  1. *P < 0.05 was required for statistical significance